ETON - CIK 0001710340
The table below shows Eton Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $10.52M | $969.00K | $6.82M | $4.82M | -$4.72M | -$22.35M |
| Capital expenditure | $333.00K | $26.00K | $0.00 | $38.00K | $9.00K | $50.00K |
| Investing cash flow | -$333.00K | -$40.01M | -$775.00K | -$2.79M | -$2.56M | -$50.00K |
| Dividends paid | - | - | - | - | - |
Eton Pharmaceuticals, Inc. reported operating cash flow of $10.52M for fiscal year 2025. That is up 986.1% from $969.00K in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$8.14M (FY 2018) to $10.52M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $815.00K | $32.59M | -$957.00K | -$134.00K | $391.00K | $31.63M |